Allogeneic Cd123Car-Cd28-Cd3Zeta-Egfrt-Expressing T-Lymphocytes
Acute Biphenotypic Leukemia
Explore 42 assets in Acute Biphenotypic Leukemia →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02159495CT.gov Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Biphenotypic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Allogeneic Cd123Car-Cd28-Cd3Zeta-Egfrt-Expressing T-Lymphocytes (this asset) | City of Hope Medical Center | P1 | CC · 43 |
| Fludarabine | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P2/3 | BB |
| Cytarabine | University of Washington | P2 | BB |
| Nivestim | Ossium Health, Inc. | P2 | BB |
| Busulfanum | Ossium Health, Inc. | P2 | BB |
| Thiotepa | Fred Hutchinson Cancer Center | P2 | BB |
| Cyclophosphamide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P3 | BB |
| Cladribine | University of Washington | P2 | BB |
| Sorafenib | University of Washington | P2 | BB |
+42 more in the Acute Biphenotypic Leukemia cohort
Other indications for Allogeneic Cd123Car-Cd28-Cd3Zeta-Egfrt-Expressing T-Lymphocytes
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| CD4+/CD56+ Hematodermic Neoplasm | — | P1 | CC · 43 |
| Adult Acute Lymphoblastic Leukemia | — | P1 | CC · 43 |
| Acute Myeloid Leukemia | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Allogeneic Cd123Car-Cd28-Cd3Zeta-Egfrt-Expressing T-Lymphocytes in Acute Biphenotypic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/allogeneic-cd123car-cd28-cd3zeta-egfrt-expressing-t-lymphocytes-acute-biphenotypic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →